In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Photon Imaging, Inc.

Latest From Photon Imaging, Inc.

Coronavirus Update: India Approves Remdesivir, Ex-Biogen Employee Charged

A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.

Coronavirus COVID-19 BioPharmaceutical

Out Of The Blocks, October 2013

Highlighting these recently formed companies: Causa Research, Indi Molecular, Nanoly Bioscience, NovoPedics, Stem Cell Theranostics, and STBL Medical Research.

Medical Device BioPharmaceutical

BioVersys AG

Bacteria continue proving themselves immensely capable of resisting formerly effective antibiotics, and likewise capable of thwarting drugmakers’ efforts to create new types of compounds. The founders of BioVersys AG believe they can identify compounds uniquely able to block certain bacterial resistance factors; they aim to develop such molecules as adjuvants to be given in combination with existing antibiotics, to help restore their potency.


Vulnerable Plaque: Medical Device's New Biological Frontier

As interest in vulnerable plaque heats up, medical device companies hope to capitalize on their earl y lead. But as vulnerable plaque shifts therapies from structural to biological, that lead many not last long. The second of a two-part series.

Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Medical Devices